



## **Supplementary Material**

**Article Title:** Antidepressant Use and Risk of Recurrent Stroke: A Population-Based Nested Case-Control Study

**Authors:** Meng-Ting Wang, PhD, RPh; Che-Li Chu, MS, BPharm; Chin-Bin Yeh, MD, PhD; Li-Chien Chang, PhD; Daniel C. Malone, PhD, RPh; and Jun-Ting Liou, MD

**DOI Number:** 10.4088/JCP.14m09134

### **List of Supplementary Material for the article**

1. [eTable 1](#) Diagnosis Codes and NIH Procedure Codes Used to Define the Potential Confounders
2. [eTable 2](#) Association Between Any Use of Antidepressants and Risk of Recurrent Stroke

### **Disclaimer**

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

© Copyright 2015 Physicians Postgraduate Press, Inc.

**Supplementary eTable 1. Diagnosis Codes and NIH Procedure Codes Used to Define the Potential Confounders**

<b>Comorbidities</b>	<b>ICD-9-CM codes</b>
Ischemic heart disease	411-414
Myocardial infarction	410
Peripheral vascular disease	440-448
Heart failure	428
Atrial fibrillation	427.3
Diabetes mellitus	250
Hypertension	401-405
COPD	491, 492, 496
Migraine	346
Chronic liver disease	571
Renal failure	584-588
Depression	296.2, 296.3, 300.4
Stroke subtype	
Hemorrhagic stroke	430-432
Ischemic stroke	433-435
Other stroke	436, 437
<b>Medical procedures</b>	<b>NIH Procedure codes</b>
Admission to an ICU	03010E, 03011F, 03012G, 03013H
Psychotherapy	45010A, 45010C, 45011B, 45012C, 45013A, 45013C, 45014B, 45015C, 45016A, 45016C, 45017B, 45018C, 45019A, 45019C, 45020B, 45021C, 45087C, 45094C, E3025C, E3026C

Abbreviations: COPD = Chronic obstructive pulmonary disease; ICU = intensive care unit; NHI = National Health Insurance.

**Supplementary eTable 2. Association between Any Use of Antidepressants<sup>a</sup> and Risk of Recurrent Stroke**

Antidepressant use	No. (%)		Odds Ratio (95% Confidence Interval)	
	Cases (n=3,536)	Controls (n=6,679)	Unadjusted	Adjusted <sup>b</sup>
Nonuse of antidepressants	3,027 (85.6)	5,907 (88.4)	1.00 [Reference]	1.00 [Reference]
SSRIs	89 (2.5)	150 (2.3)	1.17 (0.89-1.53)	1.10 (0.84-1.45)
Fluoxetine	26 (0.7)	47 (0.7)	1.09 (0.67-1.78)	1.03 (0.63-1.69)
Sertraline	21 (0.6)	47 (0.7)	0.87 (0.51-1.46)	0.79 (0.46-1.34)
Paroxetine	14 (0.4)	13 (0.2)	2.35 (1.06-5.19)	2.31 (1.04-5.13)
Citalopram	13 (0.4)	17 (0.3)	1.59 (0.76-3.34)	1.50 (0.71-3.19)
TCAs	276 (7.8)	367 (5.5)	1.47 (1.25-1.74)	1.41 (1.19-1.67)
Imipramine	155 (4.4)	209 (3.1)	1.46 (1.18-1.81)	1.41 (1.13-1.76)
Melitracen	61 (1.7)	70 (1.1)	1.73 (1.22-2.45)	1.54 (1.06-2.24)
Amitriptyline	21 (0.6)	42 (0.6)	0.97 (0.57-1.64)	1.00 (0.59-1.71)
Doxepin	16 (0.5)	18 (0.3)	1.71 (0.87-3.36)	1.68 (0.85-3.32)
Other antidepressants	144 (4.1)	255 (3.8)	1.11 (0.90-1.37)	1.04 (0.84-1.29)
Trazodone	106 (3.0)	175 (2.6)	1.20 (0.94-1.54)	1.13 (0.88-1.45)
Moclobemide	19 (0.5)	30 (0.5)	1.20 (0.67-2.15)	1.18 (0.65-2.12)
Venlafaxine	10 (0.3)	19 (0.3)	1.03 (0.48-2.22)	0.93 (0.43-2.02)

<sup>a</sup>Neither all individual antidepressants within each antidepressant class nor combinations of individual antidepressants were evaluated due to the small sample sizes.

<sup>b</sup>Adjusted for age, length of hospital stay, atrial fibrillation, diabetes mellitus, non-thiazide diuretics, cardioselective  $\beta$ -blockers, non-cardioselective  $\beta$ -blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers; antiplatelets, antipsychotics, non-selective NSAIDs.

Abbreviation: SSRIs = selective serotonin receptor inhibitors; TCAs = tricyclic antidepressants.